Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

por Tolcher, A. W., Chi, K. N., Shore, N. D., Pili, R., Molina, A., Acharya, M., Kheoh, T., Jiao, J. J., Gonzalez, M., Trinh, A., Pankras, C., Tran, N.
Publicado 2012

Marked inactivation of O(6)-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

por Tolcher, A W, Gerson, S L, Denis, L, Geyer, C, Hammond, L A, Patnaik, A, Goetz, A D, Schwartz, G, Edwards, T, Reyderman, L, Statkevich, P, Cutler, D L, Rowinsky, E K
Publicado 2003

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

por Mita, A C, Papadopoulos, K, de Jonge, M J A, Schwartz, G, Verweij, J, Mita, M M, Ricart, A, Chu, Q S-C, Tolcher, A W, Wood, L, McCarthy, S, Hamilton, M, Iwata, K, Wacker, B, Witt, K, Rowinsky, E K
Publicado 2011

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

por Papadopoulos, K P, El-Rayes, B F, Tolcher, A W, Patnaik, A, Rasco, D W, Harvey, R D, LoRusso, P M, Sachdev, J C, Abbadessa, G, Savage, R E, Hall, T, Schwartz, B, Wang, Y, Kazakin, J, Shaib, W L
Publicado 2017

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin...

por Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I., Ramanathan, R. K.
Publicado 2016